mRNA Vaccine-Elicited Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Specific T Cells Persist at 6 Months and Recognize the Delta Variant | Zendy

Bezawit A. Woldemeskel | Zendy; Caroline C. Garliss | Zendy; Joel N. Blankson | Zendy

Open Access

mRNA Vaccine-Elicited Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Specific T Cells Persist at 6 Months and Recognize the Delta Variant

Author(s) -

Bezawit A. Woldemeskel,

Caroline C. Garliss,

Joel N. Blankson

Publication year - 2021

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciab915

Subject(s) - medicine , covid-19 , coronavirus , betacoronavirus , virology , respiratory system , coronaviridae , delta , severe acute respiratory syndrome , immunology , respiratory disease , lung , outbreak , disease , infectious disease (medical specialty) , engineering , aerospace engineering

Little is known about the decay kinetics of coronavirus disease 2019 vaccine–elicited severe acute respiratory syndrome coronavirus 2–specific T cells. In this study we show a modest decline in the frequency of these T cells at 6 months and demonstrate robust expansion in response to antigen and recognition of spike peptides from the Delta variant.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research